OncoLink at ASCO 2004 CME for June 5, 2004

Last Modified: June 3, 2004

Share article


OncoLink at CFS 2003

Program Description and Objectives

The American Society of Clinical Oncology (ASCO) provides a "venue for oncologists and other healthcare professionals to come together and learn about the latest advances in cancer research." The ASCO annual meeting usually features over 3,500 abstracts covering preclinical and clinical developments on currently approved agents as well as agents not yet approved for the treatment of cancer, across all tumor types. Key opinion leaders and investigators, representing all major oncology specialties, will present cutting edge data and their interpretation of the results.

Given the volume of sessions, attendees cannot be present at all of the presentations in which they have interest. Oncology professionals that cannot attend the annual meeting will benefit from the opportunity to read unbiased, balanced reviews on key presentations from the meeting.

After completing this program, participants will be able to:

  1. Define how new therapeutic advances may be incorporated into patient care
  2. Describe new approaches under investigation that employ targeted therapies
  3. Discuss the most recent clinical trials and their clinical implications for currently available agents.

Accreditation

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of CME, Clinical Insights, Inc., and OncoLink. The American Academy of CME, Inc., is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of CME, Inc., designates this educational activity for a maximum of 1category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Pharmacists

The American Academy of CME, Inc. is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. Completion of this program provides for 1 hour (0.1 CEU) of continuing education credit. Participants must read each abstract, complete the post-evaluation form and send to AACME. Statements of credit will be mailed within six to eight weeks of receipt of forms. The program number for this symposium is 297-999-04-015-H01.

Nurses

The American Academy of CME, Inc., (AACME) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

AACME designates this educational activity 1.2 contact hours. Participants must read each abstract, complete the post-evaluation form and send to AACME. Statements of credit will be mailed within six to eight weeks of receipt of forms.

Term of Approval

This educational activity has been approved through May, 2005

Faculty Disclosures

  • M. Yoshimoto (Abstract Number 500)
    No significant financial relationships to disclose
  • J. Stec (Abstract Number 503)
    No significant financial relationships to disclose
  • M.D. Schnall (Abstract Number 504)
    Aurora Technologies – Employment or Leadership, Consultant or Advisory, Stock Ownership
  • D. F. Hayes (Abstract Number 509)
    Immunicon Corporation – Employment or Leadership, Consultant or Advisory, Stock Ownership, Honoraria, Research Funding, Expert Testimony
  • J.D. Hainsworth (Abstract Number 4502)
    No significant financial relationships to disclose
  • P. L. Nguyen (Abstract number 4503)
    No significant financial relationships to disclose
  • M. Bolla (Abstract Number 4504)
    No significant financial relationships to disclose
  • M. R. Smith (Abstract Number 4507)
    Novartis Pharmaceutical Corporation – Employment or Leadership, Consultant or Advisory, Research Funding
  • M.G. Pfreundschuh (Abstract Number 6500)
    Roche, Basel – Consultant or Advisory, Honoraria
  • W. Hiddemann (Abstract Number 6501)
    No significant financial relationships to disclose
  • H.S. Hochster (Abstract Number (6502)
    Genentech; Genentech Biooncology – Consultant or Advisory, Honoraria
  • M. Federico (Abstract Number 6507)
    No significant financial relationships to disclose

Instructions for Applying for CME

After reading all of the articles within this module you will be able to download the Program Evaluation (a pdf file), which you can print out. In order to receive your CME certificate, please complete the form and mail or fax as shown on the form.

Certificates will be mailed 6 to 8 weeks following receipt of your evaluation.


News
No new evidence found to support reversal of USPSTF 2004 recommendation against screening

Sep 22, 2010 - No new evidence has emerged warranting a change in the U.S. Preventive Services Task Force's 2004 conclusion that screening asymptomatic men for testicular cancer is unlikely to offer benefits over clinical detection, according to a literature review in the Sept. 21 issue of the Annals of Internal Medicine.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More